Management of cancer pain

被引:493
作者
Portenoy, RK [1 ]
Lesage, P [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, Dept Pain Med & Palliat Care, New York, NY 10003 USA
关键词
D O I
10.1016/S0140-6736(99)01310-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with cancer have diverse symptoms, impairments In physical and psychological functioning, and other difficulties that can undermine their quality of life. If inadequately controlled, pain can have a profoundly adverse impact on the patient and his or her family. The critical importance of pain management as part of routine cancer care has been forcefully advanced by WHO, international and national professional organisations, and governmental agencies. The prevalence of chronic pain is about 30-50% among patients with cancer who are undergoing active treatment for a solid tumour and 70-90% among those with advanced disease. Prospective surveys indicate that as many as 90% of patients could attain adequate relief with simple drug therapies, but this success rate is not achieved in routine practice. Inadequate management of pain is the result of various issues that include: undertreatment by clinicians with insufficient knowledge of pain assessment and therapy; inappropriate concerns about opioid side-effects and addiction; a tendency to give lower priority to symptom control than to disease management; patients under-reporting of pain and non-compliance with therapy; and impediments to optimum analgesic therapy in the healthcare system. To improve the management of cancer pain, every practitioner involved in the care of these patients must ensure that his or her medical information is current and that patients receive appropriate education.
引用
收藏
页码:1695 / 1700
页数:6
相关论文
共 30 条
[1]   Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life [J].
Ahmedzai, S ;
Brooks, D .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1997, 13 (05) :254-261
[2]  
*AM PAIN SOC, 1992, PRINC AN US TREATM A
[3]  
[Anonymous], 1994, AHCPR PUBLICATION
[4]   Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review [J].
Bloomfield, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (03) :1218-1225
[5]  
BRUERA E, 1990, ADV PAIN RES THER, V16, P203
[6]  
Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO
[7]  
2-T
[8]   Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[9]   THE NATURE OF SUFFERING AND THE GOALS OF MEDICINE [J].
CASSEL, EJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 306 (11) :639-645
[10]   QUALITY-OF-LIFE - CONCEPTS AND DEFINITION [J].
CELLA, DF .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1994, 9 (03) :186-192